Multiple Sclerosis

Benefits of Drug Treatment Confirmed in Recent Study

Published in Drug Week, April 6th, 2001

A front-line drug against multiple sclerosis (MS) has recently passed a long-anticipated, critical test of its effectiveness, according to a report in the March 2001 issue of Annals of Neurology.

Brain scans of patients taking glatiramer acetate (GA), sold in the United States as Copaxone, indicate that the drug significantly curtails the number of new brain lesions (injuries) caused by flare-ups of the disease and reduces the overall volume of damaged brain tissue.

Multiple sclerosis is a disorder of the nerve fibers of the brain and spinal cord. In MS, scarring (sclerosis) replaces myelin, a substance that normally surrounds the nerves...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2001-04-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry